Evidently...

Heart failure is a condition that eventually kills most of those who have it, and at the very least causes misery, anxiety, and repeated visits to hospital. The evidence base for treatment has been built up by adding one drug class to another, so patients are usually on a long list of medication about which many have little understanding. Short term outcomes can be improved by patient education, as in a trial of 223 patients with systolic heart failure who were randomised to receive 1 hour of **nurse-educator teaching** at the time of hospital discharge (*Circulation* 2005;**111**:179–85). At 6 months, the intervention group totalled fewer days dead or in hospital, and showed reduced costs. A larger community-based trial (n=1069) in all types of heart failure used a **telephonic disease management** programme and showed an average 76 days longer survival at 18 months, but no improvement in objective measures of function, hospitalisation, or healthcare costs (*Circulation* 2004;**110**:3518–26). Looking beyond heart failure, a randomised trial of **home medication review** in patients over 80 taking ≥ 2 drugs in the UK showed an actual increase in hospital admission and no benefits in quality of life or survival (*BMJ* 2005;**330**:293).

Does the thought of sorting out an **elderly** patient with **syncope** make you feel faint? Specialist units seem to do best: at the Mayo clinic, patients (mean age 64 y) were far more likely to end up with a firm diagnosis if they were randomised to a syncope evaluation unit (*Circulation* 2004;**110**:3636–45) and were a little more likely to survive the next 2 years. In a descriptive study from the UK (*J Am Geriatr Soc* 2005;**53**:74–8), older patients with **drop attacks** (mean age 77.4 y) were found to have a high incidence of soft tissue injuries and fractures, and careful investigation found an attributable diagnosis in 90%, generally cardiovascular or neurological.

Rarely does a day go by in general practice without the question of what to do about **otitis media**. In the acute situation there is the temptation to prescribe **antibiotics**—should we resist? A Canadian randomised placebo controlled trial of **amoxicillin** (*CMAJ* 2005;**172**:335–41) shows that this old friend actually works—a bit. There was less pain and fever in the first 2 days, and significantly higher resolution of symptoms at 2 weeks. And if a **middle ear effusion** follows, impairing hearing, when should we be thinking of **grommets (ventilation tubes)**? There is no clear answer in the Cochrane Review (2005:CD001801): very modest short term improvements and no long term benefits.

Hormone replacement therapy, not long ago the elixir of life for postmenopausal women, is now deeply out of fashion, even as prevention for **osteoporosis**: but it might be making a small come-back, in the form of tiny doses of **transdermal oestradiol** (0.014 mg/d). This amount of

unopposed oestrogen did not cause endometrial hyperplasia in a double blind RCT in 417 women 60–80 years of age (*Obstet Gynecol* 2004;**104**:443–51), and did improve bone mineral density. And thinking of osteoporosis, don't forget **androgen deprived men**—a cohort study of those who survived >5 years after androgen suppression treatment for prostate cancer shows that there is a dose related increase in fractures (*N Engl J Med* 2005;**352**:154–64).

If you want your child to avoid **atopic wheezing**, do you fill your house with pets, dirt, and siblings, or do you take the route of obsessive cleanliness? There is some evidence for the first strategy, but little for the second: a British cohort study (*Thorax* 2004;**59**:855–61) followed 552 British children from birth to 5.5 years and found that in susceptible children, very low levels of exposure could trigger an IgE response, which was little influenced by further increases.

A big Danish study (*Am J Epidemiol* 2004;**160**:661–7) looked prospectively at pregnancy detected by urine HCG and compared it with monthly diary entries of **alcohol intake** from both partners. Ten or more drinks per week increased the risk of **miscarriage** substantially—male intake being, if anything, a stronger risk.

How often should I use the cream, doctor? If it's a **topical corticosteroid for atopic eczema**, the chances are that you will get the same result from 1 application daily as from more, according to a systematic review and economic evaluation in *Health Technol Assess* 2004;**8**:iii,iv, 1–120.

Dandruff has provided the inspiration for some classic shampoo advertisements, but can we believe the science? **Ciclopyrox** is a new antipityrosporal agent and was put through its paces both for treatment and prevention of seborrheic dermatitis of the scalp in a double blinded multinational trial (*Arch Dermatol* 2005;**141**:47–52). The NNS (number needed to shampoo) is about 5.

The heroic age of **sleep deprived doctoring** has come to an end on one side of the Atlantic with the European Working Time Directive, but in many places in the US, interns are not so lucky. Maybe their lot will improve following a study in *N Engl J Med* 2004;**351**:1838–48 that shows a reduction in serious **medical errors** after their intensive care shifts were made shorter. In the meantime, avoid them when they are driving home: when it comes to the crunch, they have more car accidents (*N Engl J Med* 2005;**352**:125–34).

RICHARD LEHMAN MRCP, MA
Department of Primary Care, Oxford University
Oxford, UK